Immunotherapy is the first line of treatment for HCC [12], and AEG-1 inhibition synergizes with immunotherapy in breast cancer [76], thereby establishing the premise of testing this approach for HCC. The gene discussed is MTDH; the disease is hepatocellular carcinoma.